ALAMEDA, Calif.--(BUSINESS WIRE)--Celera Corporation (NASDAQ:CRA) today announced that the United States Patent and Trademark Office has issued United States Patent 7,799,530 relating to methods of determining heart attack risk by detecting the KIF6 gene variant and reduction of such increased risk by statin therapy. The KIF6 gene encodes a kinesin, a member of a family of proteins involved in microtubule-mediated intracellular transport. Previous research has shown that this variant of the KIF6 gene is associated with up to a 55% increased risk of primary and recurrent coronary heart disease (CHD) events in the placebo arms of pravastatin clinical trials, and that this increased risk was significantly reduced with statin therapy.
